



Patient Name : Mr.ASHESH KALP Age/Gender : 36 Y 10 M 22 D/M

UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH Collected : 09/Nov/2024 10:27AM
Received : 09/Nov/2024 11:14AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 09/Nov/2024 04:21PM

DEPARTMENT OF HAEMATOLOGY

Reported

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240245715

Page 1 of 14







: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID Ref Doctor : SCHIOPV38940

Emp/Auth/TPA ID

: Dr.SELF : DFHDH Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:14AM

Reported

: 09/Nov/2024 04:21PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	12.6	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	40.20	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.82	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	83.5	fL	83-101	Calculated
MCH	26.1	pg	27-32	Calculated
MCHC	31.3	g/dL	31.5-34.5	Calculated
R.D.W	16.4	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,670	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	T (DLC)			
NEUTROPHILS	62.3	%	40-80	Electrical Impedance
LYMPHOCYTES	25.2	%	20-40	Electrical Impedance
EOSINOPHILS	5.5	%	1-6	Electrical Impedance
MONOCYTES	5.9	%	2-10	Electrical Impedance
BASOPHILS	1.1	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3532.41	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1428.84	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	311.85	Cells/cu.mm	20-500	Calculated
MONOCYTES	334.53	Cells/cu.mm	200-1000	Calculated
BASOPHILS	62.37	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.47		0.78- 3.53	Calculated
PLATELET COUNT	159000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	12	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC WITH OCCASIONAL MICROCYTIC HYPOCHROMIC CELLS.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 14



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240245715





: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225 : SCHIOPV38940

Visit ID Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : DFHDH Collected

: 09/Nov/2024 10:27AM

Received Reported : 09/Nov/2024 11:14AM : 09/Nov/2024 04:21PM

Status

: Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240245715

Page 3 of 14





Patient Name : Mr.ASHESH KALP
Age/Gender : 36 Y 10 M 22 D/M
UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH Collected : 09/Nov/2024 10:27AM
Received : 09/Nov/2024 11:14AM
Reported : 09/Nov/2024 04:27PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
BLOOD GROUP ABO AND RH FACTOR	, WHOLE BLOOD EDTA			
BLOOD GROUP TYPE	AB			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 14









: Mr.ASHESH KALP

Age/Gender UHID/MR No : 36 Y 10 M 22 D/M : SCHI.0000025225

Visit ID

: SCHIOPV38940

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : DFHDH

Collected

: 09/Nov/2024 01:42PM

Received : 09/Nov/2024 02:55PM

Reported

: 09/Nov/2024 04:41PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, FASTING, NAF PLASMA	95	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	95	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 14



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:PLP1488004







Patient Name : Mr.ASHESH KALP

Age/Gender : 36 Y 10 M 22 D/M

UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH Collected : 09/Nov/2024 10:27AM

Received : 09/Nov/2024 12:57PM

Reported : 09/Nov/2024 02:38PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.4	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	108	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:


REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
- Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF > 25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 14





SIN No:EDT240094093





: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID

: SCHIOPV38940

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: DFHDH

Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:12AM

Reported

Status

: 09/Nov/2024 01:26PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIPID PROFILE , SERUM	<u>'</u>	'		·
TOTAL CHOLESTEROL	182	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	172	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	45	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	137	mg/dL	<130	Calculated
LDL CHOLESTEROL	102.6	mg/dL	<100	Calculated
VLDL CHOLESTEROL	34.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.04		0-4.97	Calculated
ATHEROGENIC INDEX (AIP)	0.22		<0.11	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Page 7 of 14









: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No Visit ID : SCHI.0000025225

Ref Doctor

: SCHIOPV38940

Emp/Auth/TPA ID : DFHDH

: Dr.SELF

Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:12AM

Reported

: 09/Nov/2024 01:26PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.50	mg/dL	0.20-1.30	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.20	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	29	U/L	<50	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	29.0	U/L	17-59	UV with P-5-P
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	1.0		<1.15	Calculated
ALKALINE PHOSPHATASE	68.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.60	g/dL	6.3-8.2	Biuret
ALBUMIN	4.60	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.00	g/dL	2.0-3.5	Calculated
A/G RATIO	1.53		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- *AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.*ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:*ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.*Bilirubin elevated- predominantly direct , To establish the hepatic origin correlation with elevated GGT helps.
- 3. Synthetic function impairment:*Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 8 of 14









: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID

: SCHIOPV38940

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : DFHDH Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:12AM

Reported

: 09/Nov/2024 01:26PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SER	RUM		
CREATININE	1.00	mg/dL	0.66-1.25	Creatinine amidohydrolase
UREA	25.60	mg/dL	19-43	Urease
BLOOD UREA NITROGEN	12.0	mg/dL	8.0 - 23.0	Calculated
URIC ACID	5.70	mg/dL	3.5-8.5	Uricase
CALCIUM	10.40	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	3.10	mg/dL	2.5-4.5	PMA Phenol
SODIUM	144	mmol/L	135-145	Direct ISE
POTASSIUM	4.2	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	109	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	7.60	g/dL	6.3-8.2	Biuret
ALBUMIN	4.60	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.00	g/dL	2.0-3.5	Calculated
A/G RATIO	1.53		0.9-2.0	Calculated

Page 9 of 14









: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID Ref Doctor : SCHIOPV38940

Emp/Auth/TPA ID

: Dr.SELF : DFHDH Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:12AM : 09/Nov/2024 01:26PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	12.00	U/L	15-73	Glyclyclycine Nitoranalide

Page 10 of 14









Patient Name : Mr.ASHESH KALP Age/Gender : 36 Y 10 M 22 D/M

UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH Collected : 09/Nov/2024 10:27AM

Received : 09/Nov/2024 12:59PM Reported : 09/Nov/2024 02:40PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method	
THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM					
TRI-IODOTHYRONINE (T3, TOTAL)	1.06	ng/mL	0.87-1.78	CLIA	
THYROXINE (T4, TOTAL)	12.73	μg/dL	5.48-14.28	CLIA	
THYROID STIMULATING HORMONE (TSH)	2.135	μIU/mL	0.38-5.33	CLIA	

Comment:


For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions			
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis			
High	N	N	N	clinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.			
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism			
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy			
Low	N	N	N	oclinical Hyperthyroidism			
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism			
Low	N	High	High	Thyroiditis, Interfering Antibodies			
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes			

Page 11 of 14





SIN No:SPL24146264







: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID

: SCHIOPV38940

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: DFHDH

Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 12:59PM

Reported

Status

: 09/Nov/2024 02:40PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

]	High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma
---	------	------	------	------	--

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24146264



Page 12 of 14





: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID Ref Doctor : SCHIOPV38940

Emp/Auth/TPA ID

: Dr.SELF : DFHDH Collected Received : 09/Nov/2024 10:27AM

Reported

: 09/Nov/2024 02:05PM : 09/Nov/2024 04:06PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
COMPLETE URINE EXAMINATION (CUE) , URINE			<u>'</u>
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Physical Measurement
pH	7.0		5-7.5	Double Indicator
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	Protein Error Of Indicator
GLUCOSE	NEGATIVE		NEGATIVE	Glucose Oxidase
URINE BILIRUBIN	NEGATIVE		NEGATIVE	Azo Coupling Reaction
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	Sodium Nitro Prusside
UROBILINOGEN	NORMAL		NORMAL	Modifed Ehrlich Reaction
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Leucocyte Esterase
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOP	Y		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	Microscopy
RBC	ABSENT	/hpf	0-2	Microscopy
CASTS	ABSENT		0-2 Hyaline Cast	Microscopy
CRYSTALS	ABSENT		ABSENT	Microscopy

Comment:

All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods. Microscopy findings are reported as an average of 10 high power fields.

Page 13 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:UR2419340





: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID Ref Doctor : SCHIOPV38940

Emp/Auth/TPA ID

: Dr.SELF : DFHDH

Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 02:02PM

Reported Status

: 09/Nov/2024 04:06PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	GOD-POD
Test Name	Result	Unit	Bio. Ref. Interval	Method
		-		

*** End Of Report ***

Page 14 of 14









Patient Name : Mr.ASHESH KALP Age/Gender : 36 Y 10 M 22 D/M UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH

Collected : 09/Nov/2024 10:27AM Received : 09/Nov/2024 02:02PM

Reported : 09/Nov/2024 04:06PM

: Final Report : ARCOFEMI HEALTHCARE LIMITED Sponsor Name

TERMS AND CONDITIONS GOVERNING THIS REPORT

- 1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understandreporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever.
- 2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.

Status

- 3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
- 4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies.
- 5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of the laboratory.
- 6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.

hweta Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:UF012161





Name Mr. ASHESH KALP Age: 36 Y

UHID:SCHI.0000025225

Sex: M

SCHI.0000025225

Address: DEVLI KĤANPUR Plan: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN INDIA OP AGREEMENT	OP Number: SCHIOPV38940 Bill No : SCHI-OCR-12914 Date : 09.11.2024 10:08
Sno Serive Type/ServiceName	Department
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS	MALE - 2D ECHO - PAN INDIA - FY2324
I GAMMA GLUTAMYL TRANFERASE (GGT)	
(2) DECHO - Pm	
3 LIVER FUNCTION TEST (LFT)	
4 GLUCOSE, FASTING	
5 HEMOGRAM + PERIPHERAL SMEAR	
6 DIET CONSULTATION	
7 COMPLETE URINE EXAMINATION	
8 URINE GLUCOSE(POST PRANDIAL)	
9 PERIPHERAL SMEAR	
ORCG	
11 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
12 DENTAL CONSULTATION	
13 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL) - 1:30
14 URINE GLUCOSE(FASTING)	
15 HbA1c, GLYCATED HEMOGLOBIN	And the second s
6 RAY CHEST PA	
FIENT CONSULTATION (5)	
18 FITNESS BY GENERAL PHYSICIAN	
19 BLOOD GROUP ABO AND RH FACTOR	
20 LIPID PROFILE	
21 BODY MASS INDEX (BMI)	
OPPHAL BY GENERAL PHYSICIAN	
23ULTRASOUND - WHOLE ABDOMEN	
24 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	

PHC_Desk

From:

Mediwheel < wellness@mediwheel.in >

Sent:

07 November 2024 16:19

To: Cc:


phc.klc@apollospectra.com customercare@mediwheel.in

Subject:

Health Check up Booking Confirmed Request(22E35932), Package Code-

PKG10000366, Beneficiary Code-300039





.01144.1198940

Hi Apollo Spectra - Nehru Enclave,

The following booking has been confirmed. It is requested to honor the said booking & provide priority services to our client

Hospital

: Mediwheel Full Body Annual Plus

Package Name

Patient Package: Mediwheel Full Body Health Checkup Male Below 40

Contact Details: 7859906525

Appointment

Date

: 09-11-2024

Confirmation

Status

: Booking Confirmed

Preferred Time: 08:30 AM - 09:00 AM

The second second	Mambay Ind		i bodhing &
Booked Member Name	Member Inf Age	Gender	
MR. KALP ASHESH	36 year	Male	


We request you to facilitate the employee on priority.

Thanks,

Mediwheel Team

Please Download Mediwheel App





CERTIFICATE OF MEDICAL FITNESS

of After	Ashesh on 911 reviewing the medical history and on clinical examination it has been found e/she is	
LILAC 11V	J SIIC 15	T
	Medically Fit	-
9	Fit with restrictions/recommendations	Ť
	Though following restrictions have been revealed, in my opinion, these are not impediments to the job.	
	1	
	2	
	3	
	However the employee should follow the advice/medication that has been communicated to him/her.	
	Review after	
٥	Currently Unfit. Review after recommended	
Φ.	Unfit	-

Medical Officer
The Apollo Clinic, Uppal

This certificate is not meant for medico-legal purposes

PREVENTIVE HEALTH CARE SUMMARY

NAME . A .	EALTH CARE SUMMARY
NAME: - Ashesy AGE/GENDER: - 364M PANEL: Alcofery	UHID No: 25 227 RECEIPT No:- EXAMINED ON:-
Chief Complaints:	Ac
Past History:	
DM Hypertension CAD Personal History:	CVA : Nil Cancer : Nil Other : Nil
Alcohol Smoking : (Nil Nil Nil	Activity : Active Allergies : Nil
Family History: NS ,	· NII
General Physical Examination: Height	^
Weight 72: cms Kgs	Pulse Ish bpm BP mmHg
Rest of examination was within normal limits.	120/80 mining
Systemic Examination:	
CVS : Normal Respiratory system : Normal Abdominal system : Normal CNS : Normal Others : Normal	

PREVENTIVE HEALTH CARE SUMMARY

NAME: - Leho 1	DESCRIPTION OF THE PROPERTY OF	
AGE:-	UHID No:	
JUA:	RECEIPT No : -	
PANEL:	EXAMINED ON : -	

Investigations:

• All the reports of tests and investigations are attached herewith

46-2-6 79 172

Recommendation:

Ty grandred XT 102x 1-2 monts

Cap Miced Der 102x 2 weeks

Cap Advantage 5 400 x 3 most

Cap Advantage 5 400 x 2 most

Dr. Norman Renorman

Consultant Physician

Consultant Physician



Name:	ASHESH KALP	Age/Sex:	36	Yrs./M
UHID:	25225	,		
Ref By:	APOLLO SPECTRA	Date:-	09.11.	2024

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and echotexture. Intrahepatic biliary radicles are not dilated. No focal or diffuse lesion is seen. CBD and portal vein are normal in caliber.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Prostate: is normal in size and echotexture.

No free fluid seen.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab. Investigations.

DR. DEFINA AGARWAI Consultant Radiologist

Dr. DEEPIKA AGARWAL

Consultant Radiologist DMC No. 56777

Apollo Speciality Hospitals (P) Ltd. A-2, Chirag Enclave, Greater Kailash-1 New Delhi-110048

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

Mr. Asherh Kalp 36/N1 Apollo Sp Specialists in Surgery Cyc chickup Howing glass No Ho systemic disens MUT 197 musty coloury (mormal V4 (6/6 Buy new Acceptance of Blf-Ale Shit Lours exam?

Shit Lourneys exam?

Als Mormal B/L

Pupil reachion Mormal B/L

Fundus (WML B/L.

Danakhir alillan

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

Dr. Swaraj Mishra - Dshesh MS (ENT) Specialists in Surgery Sr. Consultant DMC-62047 09/11/26 For Appointment:+ 91 11 40465555 Mob.:+ 91 9910995018 NED Clinically

> Dr. Swaraj Mishra MS (ENT) DMC: 62047

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospitals Pvt. Ltd.



DIGITAL X-RAY REPORT

NAME, ACHECITY IN	
NAME: ASHESH KALP UHID NO: 25225	DATE: 09.11.2024
OHID NO: 25225	AGE: 36YRS/ SEX: M

X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. DEERIKA AGARWAL Consultant Radiologist

> Dr. DEEP!KA AGARWAL Consultant Padiologist

DMC No. 56777 Apollo Speciality Hospitals (P) Ltd. A-2, Chirag Enclave, Greater Kailash-1 New Delhi-110048

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

09.11.2024



Mr. Ashem Kalp 36 Yrs Male


elc-Regular Chech-UP MH-NRH

MIH - NRH

0/6 - Stainst, Calculust

Advised. Full mouth dual Prophylaris.

Dr. Aramika





: Mr. ASHESH KALP

UHID Conducted By: Referred By

: SCHI.0000025225

: Dr. MUKESH K GUPTA

Age

OP Visit No Conducted Date : 36 Y/M

: SCHIOPV38940 : 09-11-2024 17:17

MITRAL VALVE

Morphology AML-Normal/Thickening/Calcification/Flutter/Vegetation/Prolapse/SAM/Doming.

PML-Normal/Thickening/Calcification/Prolapse/Paradoxical motion/Fixed.

Subvalvular deformity Present/Absent.

Doppler

Normal/Abnormal Mitral Stenosis

Present/Absent MDG

Score E>ARR Interval_ MVA

msec _cm²

EDG __mmHg Mitral Regurgitation

_mmHg Absent/Trivial/Mild/Moderate/Severe.

TRICUSPID VALVE

Morphology Doppler

Normal/Atresia/Thickening/Calcification/Prolapse/Vegetation/Doming.

Normal/Abnormal

Tricuspid stenosis

Present/Absent

RR interval_

EDG _mmHg Tricuspid regurgitation: $MDG_{\underline{}}$ _mmHg

Absent/Trivial/Mild/Moderate/Severe Fragmented signals

Velocity_ _msec. Pred. RVSP=RAP+_

PULMONARY VALVE

Morphology

Normal/Atresia/Thickening/Doming/Vegetation.

Doppler

Normal/Abnormal. Pulmonary stenosis

Present/Absent

Level

__mmHg Pulmonary annulus___mm

Pulmonary regurgitation Early diastolic gradient_

Absent/Trivial/Mild/Moderate/Severe _mmHg.

End diastolic gradient_mmHg

AORTIC VALVE

Morphology

Normal/Thickening/Calcification/Restricted opening/Flutter/Vegetation

No. of cusps 1/2/3/4

Doppler

Normal/Abnormal

Aortic stenosis

Present/Absent PSG_ _mmHg Level

Aortic annulus_

Aortic regurgitation

Absent/Trivial/Mild/Moderate/Severe.

Measureme	nts	Normal Values	Measurements		Normal values
Aorta	2.7	(2.0 - 3.7cm)	LA es	2.9	(1.9 - 4.0 cm)
LV es	2.4	(2.2 - 4.0 cm)	LV ed	4.4	(3.7 - 5.6cm)
IVS ed	0.9	(0.6 - 1.1 cm)	PW (LV)	0.8	(0.6 - 1.1 cm)
RV ed		(0.7 - 2.6cm)	RV Anterior wall		(upto 5 mm)
LVVd (ml)			LVVs (ml)		· 1
EF	65%	(54%-76%)	IVS motion	Norr	nal/Flat/Paradoxical

CHAMBERS:

Regional wall motion abnormality

Normal/Enlarged/Clear/Thrombus/Hypertrophy

Normal/Reduced

Contraction

Absent

LA

Normal/Enlarged/Clear/Thrombus

RA

Normal/Enlarged/Clear/Thrombus

RV

Normal/Enlarged/Clear/Thrombus

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospitals Pvt. Ltd.

CIN - U85100TG2009PTC099414



PERICARDIUM

COMMENTS & SUMMARY v Normal LV systolic function v No RWMA, LVEF=65%

- No AR, PR, MR & TR
- No I/C clot or mass
- Good RV function
- Normal pericardium v No pericardial effusion

Dr. M K Gupta M.B.B.S, MD, FIACM Senior Consultant Cardiologist



Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospitals Pvt. Ltd.

CIN - U85100TG2009PTC099414





Patient Name : Mr.ASHESH KALP Age/Gender : 36 Y 10 M 22 D/M

UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH Collected : 09/Nov/2024 10:27AM
Received : 09/Nov/2024 11:14AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 09/Nov/2024 04:21PM

DEPARTMENT OF HAEMATOLOGY

Reported

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240245715

Page 1 of 14







: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID Ref Doctor : SCHIOPV38940

Emp/Auth/TPA ID

: Dr.SELF : DFHDH Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:14AM

Reported

: 09/Nov/2024 04:21PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	12.6	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	40.20	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.82	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	83.5	fL	83-101	Calculated
MCH	26.1	pg	27-32	Calculated
MCHC	31.3	g/dL	31.5-34.5	Calculated
R.D.W	16.4	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,670	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUN	T (DLC)			
NEUTROPHILS	62.3	%	40-80	Electrical Impedance
LYMPHOCYTES	25.2	%	20-40	Electrical Impedance
EOSINOPHILS	5.5	%	1-6	Electrical Impedance
MONOCYTES	5.9	%	2-10	Electrical Impedance
BASOPHILS	1.1	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3532.41	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1428.84	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	311.85	Cells/cu.mm	20-500	Calculated
MONOCYTES	334.53	Cells/cu.mm	200-1000	Calculated
BASOPHILS	62.37	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.47		0.78- 3.53	Calculated
PLATELET COUNT	159000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	12	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC WITH OCCASIONAL MICROCYTIC HYPOCHROMIC CELLS.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 14



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240245715





: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225 : SCHIOPV38940

Visit ID Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : DFHDH Collected

: 09/Nov/2024 10:27AM

Received Reported : 09/Nov/2024 11:14AM : 09/Nov/2024 04:21PM

Status

: Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240245715

Page 3 of 14





Patient Name : Mr.ASHESH KALP
Age/Gender : 36 Y 10 M 22 D/M
UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH Collected : 09/Nov/2024 10:27AM
Received : 09/Nov/2024 11:14AM
Reported : 09/Nov/2024 04:27PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
BLOOD GROUP ABO AND RH FACTOR	R, WHOLE BLOOD EDTA			
BLOOD GROUP TYPE	AB			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 14









: Mr.ASHESH KALP

Age/Gender UHID/MR No : 36 Y 10 M 22 D/M : SCHI.0000025225

Visit ID

: SCHIOPV38940

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : DFHDH

Collected

: 09/Nov/2024 01:42PM

Received : 09/Nov/2024 02:55PM

Reported

: 09/Nov/2024 04:41PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, FASTING, NAF PLASMA	95	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	95	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 14



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:PLP1488004







Patient Name : Mr.ASHESH KALP

Age/Gender : 36 Y 10 M 22 D/M

UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH Collected : 09/Nov/2024 10:27AM

Received : 09/Nov/2024 12:57PM

Reported : 09/Nov/2024 02:38PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.4	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	108	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:


REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 - 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
- Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF > 25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 14





SIN No:EDT240094093





: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID

: SCHIOPV38940

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : DFHDH Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:12AM

Reported Status : 09/Nov/2024 01:26PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIPID PROFILE , SERUM	<u>'</u>	<u>'</u>	<u>'</u>	
TOTAL CHOLESTEROL	182	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	172	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	45	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	137	mg/dL	<130	Calculated
LDL CHOLESTEROL	102.6	mg/dL	<100	Calculated
VLDL CHOLESTEROL	34.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.04		0-4.97	Calculated
ATHEROGENIC INDEX (AIP)	0.22		<0.11	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Page 7 of 14









: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No Visit ID : SCHI.0000025225

Ref Doctor

: SCHIOPV38940

Emp/Auth/TPA ID : DFHDH

: Dr.SELF

Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:12AM

Reported

: 09/Nov/2024 01:26PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.50	mg/dL	0.20-1.30	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.20	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	29	U/L	<50	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	29.0	U/L	17-59	UV with P-5-P
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	1.0		<1.15	Calculated
ALKALINE PHOSPHATASE	68.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.60	g/dL	6.3-8.2	Biuret
ALBUMIN	4.60	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.00	g/dL	2.0-3.5	Calculated
A/G RATIO	1.53		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- *AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.*ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:*ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.*Bilirubin elevated- predominantly direct , To establish the hepatic origin correlation with elevated GGT helps.
- 3. Synthetic function impairment:*Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 8 of 14









: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID

: SCHIOPV38940

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : DFHDH Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:12AM

Reported

: 09/Nov/2024 01:26PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SER	RUM		
CREATININE	1.00	mg/dL	0.66-1.25	Creatinine amidohydrolase
UREA	25.60	mg/dL	19-43	Urease
BLOOD UREA NITROGEN	12.0	mg/dL	8.0 - 23.0	Calculated
URIC ACID	5.70	mg/dL	3.5-8.5	Uricase
CALCIUM	10.40	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	3.10	mg/dL	2.5-4.5	PMA Phenol
SODIUM	144	mmol/L	135-145	Direct ISE
POTASSIUM	4.2	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	109	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	7.60	g/dL	6.3-8.2	Biuret
ALBUMIN	4.60	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.00	g/dL	2.0-3.5	Calculated
A/G RATIO	1.53		0.9-2.0	Calculated

Page 9 of 14









: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID Ref Doctor : SCHIOPV38940

Emp/Auth/TPA ID

: Dr.SELF : DFHDH Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 11:12AM : 09/Nov/2024 01:26PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	12.00	U/L	15-73	Glyclyclycine Nitoranalide

Page 10 of 14









Patient Name : Mr.ASHESH KALP Age/Gender : 36 Y 10 M 22 D/M

UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH Collected : 09/Nov/2024 10:27AM

Received : 09/Nov/2024 12:59PM Reported : 09/Nov/2024 02:40PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
THYROID PROFILE TOTAL (T3, T4, TS)	H), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.06	ng/mL	0.87-1.78	CLIA
THYROXINE (T4, TOTAL)	12.73	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	2.135	μIU/mL	0.38-5.33	CLIA

Comment:


For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 11 of 14





SIN No:SPL24146264







: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID

: SCHIOPV38940

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: DFHDH

Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 12:59PM

Reported

Status

: 09/Nov/2024 02:40PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

]	High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma
---	------	------	------	------	--

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24146264



Page 12 of 14





: Mr.ASHESH KALP

Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID Ref Doctor : SCHIOPV38940

Emp/Auth/TPA ID

: Dr.SELF : DFHDH Collected Received : 09/Nov/2024 10:27AM

Reported

: 09/Nov/2024 02:05PM : 09/Nov/2024 04:06PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
COMPLETE URINE EXAMINATION (CUE) , URINE		<u>'</u>	<u>'</u>
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Physical Measurement
рН	7.0		5-7.5	Double Indicator
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	Protein Error Of Indicator
GLUCOSE	NEGATIVE		NEGATIVE	Glucose Oxidase
URINE BILIRUBIN	NEGATIVE		NEGATIVE	Azo Coupling Reaction
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	Sodium Nitro Prusside
UROBILINOGEN	NORMAL		NORMAL	Modifed Ehrlich Reaction
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Leucocyte Esterase
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOP	Y		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	Microscopy
RBC	ABSENT	/hpf	0-2	Microscopy
CASTS	ABSENT		0-2 Hyaline Cast	Microscopy
CRYSTALS	ABSENT		ABSENT	Microscopy

Comment:

All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods. Microscopy findings are reported as an average of 10 high power fields.

Page 13 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:UR2419340





Patient Name : Mr.ASHESH KALP Age/Gender

: 36 Y 10 M 22 D/M

UHID/MR No

: SCHI.0000025225

Visit ID Ref Doctor : SCHIOPV38940

Emp/Auth/TPA ID

: Dr.SELF

: DFHDH

Collected

: 09/Nov/2024 10:27AM

Received

: 09/Nov/2024 02:02PM : 09/Nov/2024 04:06PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	GOD-POD
Test Name	Result	Unit	Bio. Ref. Interval	Method

*** End Of Report ***

Page 14 of 14









Patient Name : Mr.ASHESH KALP Age/Gender : 36 Y 10 M 22 D/M UHID/MR No : SCHI.0000025225

Visit ID : SCHIOPV38940

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : DFHDH

Collected : 09/Nov/2024 10:27AM Received : 09/Nov/2024 02:02PM

Reported : 09/Nov/2024 04:06PM

: Final Report : ARCOFEMI HEALTHCARE LIMITED Sponsor Name

TERMS AND CONDITIONS GOVERNING THIS REPORT

- 1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understandreporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever.
- 2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.

Status

- 3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
- 4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies.
- 5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of the laboratory.
- 6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.

hweta Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:UF012161



Patient Name : Mr. ASHESH KALP Age : 36 Y/M

UHID : SCHI.0000025225 OP Visit No : SCHIOPV38940 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 09-11-2024 17:17

Referred By : SELF

MITRA	AL V	JAL	VE
IVII I IN	1 1	$_{I}$ $_{I}$	V 12

Morphology AML-Normal/Thickening/Calcification/Flutter/Vegetation/Prolapse/SAM/Doming.

PML-Normal/Thickening/Calcification/Prolapse/Paradoxical motion/Fixed.

Subvalvular deformity Present/Absent.

Doppler Normal/Abnormal E>A

RR Interval msec MVA cm² Mitral Stenosis Present/Absent

EDG mmHg MDG mmHg

Mitral Regurgitation Absent/Trivial/Mild/Moderate/Severe.

TRICUSPID VALVE

Normal/Atresia/Thickening/Calcification/Prolapse/Vegetation/Doming. Morphology

Normal/Abnormal Doppler

> Tricuspid stenosis Present/Absent RR interval msec.

EDG mmHg MDG mmHg

Absent/Trivial/Mild/Moderate/Severe Fragmented signals Tricuspid regurgitation:

Velocity msec. Pred. RVSP=RAP+ mmHg

PULMONARY VALVE

Normal/Atresia/Thickening/Doming/Vegetation. Morphology

Doppler Normal/Abnormal.

> Pulmonary stenosis Present/Absent Level

> > PSG mmHg Pulmonary annulus mm

Absent/Trivial/Mild/Moderate/Severe Pulmonary regurgitation

mmHg. Early diastolic gradient End diastolic gradient mmHg

AORTIC VALVE

Normal/Thickening/Calcification/Restricted opening/Flutter/Vegetation Morphology

 $\overline{\text{No. of cusps}}$ 1/2/3/4

Normal/Abnormal Doppler

> Aortic stenosis Present/Absent Level

PSG mmHg Aortic annulus mm

Absent/Trivial/Mild/Moderate/Severe. Aortic regurgitation

Normal Values Normal values Measurements Measurements

	: Mr. ASHESH K	ALP	Age		: 36 Y/M	
	: SCHI.00000252	25	OP Visi	t No	: SCHIOPV38940	
	: Dr. MUKESH k	K GUPTA	Conduct	ted Date	: 09-11-2024 17:17	
	: SELF					
2.7	(2.0 - 3.7cm)	LA es	2.9	(1.9 - 4.0 cm)		
2.4	(2.2 - 4.0 cm)	LV ed	4.4	(3.7 - 5.6 cm)		
0.9	(0.6 - 1.1 cm)	PW (LV)	0.8	(0.6 - 1.1 cm)		
	(0.7 - 2.6cm)	RV Anterior wall		(upto 5 mm)		
		LVVs (ml)				
65%	(54%-76%)	IVS motion	Norr	nal/Flat/Paradox	ical	
	2.4 0.9	: SCHI.00000252 : Dr. MUKESH K : SELF 2.7 (2.0 – 3.7cm) 2.4 (2.2 – 4.0cm) 0.9 (0.6 – 1.1cm) (0.7 – 2.6cm)	: SELF 2.7 (2.0 – 3.7cm) LA es 2.4 (2.2 – 4.0cm) LV ed 0.9 (0.6 – 1.1cm) PW (LV) (0.7 – 2.6cm) RV Anterior wall LVVs (ml)	: SCHI.0000025225 OP Visite	: SCHI.0000025225 OP Visit No : Dr. MUKESH K GUPTA Conducted Date : SELF 2.7 (2.0 - 3.7cm) LA es 2.9 (1.9 - 4.0cm) 2.4 (2.2 - 4.0cm) LV ed 4.4 (3.7 - 5.6cm) 0.9 (0.6 - 1.1cm) PW (LV) 0.8 (0.6 - 1.1cm) (0.7 - 2.6cm) RV Anterior wall LVVs (ml)	: SCHI.0000025225 OP Visit No : SCHIOPV38940 : Dr. MUKESH K GUPTA Conducted Date : 09-11-2024 17:17 : SELF 2.7 (2.0 – 3.7cm) LA es 2.9 (1.9 – 4.0cm) 2.4 (2.2 – 4.0cm) LV ed 4.4 (3.7 – 5.6cm) 0.9 (0.6 – 1.1cm) PW (LV) 0.8 (0.6 – 1.1cm) (0.7 – 2.6cm) RV Anterior wall LVVs (ml)

CHAMBERS:

LV <u>Normal</u>/Enlarged/<u>Clear</u>/Thrombus/Hypertrophy

Contraction Normal/Reduced

Regional wall motion abnormality Absent

LA <u>Normal/Enlarged/Clear/Thrombus</u>

RA <u>Normal/Enlarged/Clear/Thrombus</u>

RV <u>Normal</u>/Enlarged/<u>Clear</u>/Thrombus

PERICARDIUM

COMMENTS & SUMMARY

- v Normal LV systolic function
- v No RWMA, LVEF=65%
- v No AR,PR,MR & TR
- v No I/C clot or mass
- v Good RV function
- v Normal pericardium
- No pericardial effusion

Patient Name : Mr. ASHESH KALP Age : 36 Y/M

UHID : SCHI.0000025225 OP Visit No : SCHIOPV38940 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 09-11-2024 17:17

Referred By : SELF

Dr. M K Gupta M.B.B.S, MD,FIACM Senior Consultant Cardiologist Patient Name : Mr. ASHESH KALP Age : 36 Y/M

UHID : SCHI.0000025225 OP Visit No : SCHIOPV38940

Conducted By: : Conducted Date :

Referred By : SELF

Patient Name : Mr. ASHESH KALP Age : 36 Y/M

UHID : SCHI.0000025225 OP Visit No : SCHIOPV38940

Conducted By : Conducted Date :

Referred By : SELF